Analyst consensus rating
Tarsus Pharmaceuticals Analyst Rating: none
TARS is rated none by 7 analysts with a $94.86 target. As of 2026-09-01.
Direct answer
Tarsus Pharmaceuticals's consensus rating is none.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $94.86.
Forecast evidence checked September 1, 2026.
Get free Tarsus Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $74.24
- Average price target
- $94.86
- High price target
- $104.00
- Low price target
- $84.00
- Low target gap
- +13.1%
- Target upside
- +27.8%
- High target gap
- +40.1%
- Target range width
- 26.9%
- Consensus rating
- none
- Analysts
- 7
- Evidence date
- September 1, 2026
- Valid through
- September 8, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $94.86.
How far are Tarsus Pharmaceuticals's low and high targets from the recorded price?
The low target implies +13.1%, while the high target implies +40.1%.
How many analysts are included in Tarsus Pharmaceuticals's consensus?
The verified consensus includes 7 analysts.
How is Tarsus Pharmaceuticals's target upside or downside calculated?
The average target of $94.86 is divided by the recorded price of $74.24, then one is subtracted to produce +27.8%. This does not guarantee a future return.
When was Tarsus Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-09-01. The dataset is valid through 2026-09-08.